LEGN · Legend Biotech Corporation American Depositary Shares
View on chartInsiders & Stakes
| Ingrid Zhang Chief Executive Officer | ▲ Buy | Grant | 1,131,860 Shares held | 9/15/2026 | View profile |
| Huang Ying Chief Executive Officer | ▼ Sell | Gift | 238,490 Shares held | 6/30/2026 | View profile |
| Ji Darren Xiaohui | ▲ Buy | Grant | 92,103 Shares held | 9/24/2026 | View profile |
| Casey Patrick John | ▲ Buy | Grant | 69,590 Shares held | 9/24/2026 | View profile |
| Mao Li | ▲ Buy | Grant | 65,316 Shares held | 9/24/2026 | View profile |
| Salovey Peter | ▲ Buy | Grant | 55,096 Shares held | 9/24/2026 | View profile |
| Tomas J. Heyman Director | ▲ Buy | Grant | 53,720 Shares held | 9/24/2026 | View profile |
| Corazon (Corsee) D. Sanders Director | ▼ Sell | Open Market | 52,731 Shares held | 9/29/2026 | View profile |
| BASH ALAN Interim CEO | ▲ Buy | Grant | 35,142 Shares held | 8/14/2026 | View profile |
| Santos Carlos E Chief Financial Officer | ▼ Sell | Open Market | 14,246 Shares held | 9/21/2026 | View profile |
Transaction History
| Corazon (Corsee) D. Sanders | ▼ Sell | Open Market | 27,370 | $259K | 9/29/2026 |
| Salovey Peter | ▲ Buy | Grant | 28,330 | $0 | 9/24/2026 |
| Tomas J. Heyman | ▲ Buy | Grant | 20,986 | $0 | 9/24/2026 |
| Mao Li | ▲ Buy | Grant | 20,986 | $0 | 9/24/2026 |
| Casey Patrick John | ▲ Buy | Grant | 20,986 | $0 | 9/24/2026 |
| Ji Darren Xiaohui | ▲ Buy | Grant | 28,330 | $0 | 9/24/2026 |
| Corazon (Corsee) D. Sanders | ▲ Buy | Grant | 20,986 | $0 | 9/24/2026 |
| Santos Carlos E | ▲ Buy | Grant | 19,676 | $0 | 9/21/2026 |
| Santos Carlos E | ▼ Sell | Open Market | 5,430 | $50K | 9/21/2026 |
| Ingrid Zhang | ▲ Buy | Grant | 1,131,860 | $0 | 9/15/2026 |
| BASH ALAN | ▲ Buy | Grant | 4,908 | $0 | 8/14/2026 |
| Casey Patrick John | ▼ Sell | Open Market | 6,000 | $89K | 6/30/2026 |
| Huang Ying | ▼ Sell | Gift | 3,382 | $0 | 6/30/2026 |
| Huang Ying | ▼ Sell | Open Market | 5,566 | $82K | 6/25/2026 |
| Huang Ying | ▼ Sell | Open Market | 9,936 | $87K | 3/25/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Legend Biotech Faces Revised Valuation After CARVYKTI Data
Legend Biotech’s valuation is under review after the release of five‑year CARVYKTI data. JP Morgan and RBC Capital both lowered their price targets to $33 and $56 respectively, signaling a more cautious outlook. The stock is near its 52‑week low and currently tests support at $18.75, adding pressure to the revised targets.
Legend Biotech Faces Revised Valuation After CARVYKTI Data. Legend Biotech’s valuation is under review after the release of five‑year CARVYKTI data. JP Morgan and RBC Capital both lowered their price targets to $33 and $56 respectively, signaling a more cautious outlook. The stock is near its 52‑week low and currently tests support at $18.75, adding pressure to the revised targets.